The Journal of Practical Medicine >
Expression and significance of ubiquitin⁃specific proteases 20 and hypoxia inducible factor⁃1α in breast cancer
Received date: 2024-01-23
Online published: 2024-08-26
Objective To explore the changes and significane of USP20 and HIF-α expression in breast cancer. Methods Following transfection of shRNA-USP20 lentivirus into breast cancer MDA-MB-231 cells， the gene and protein expression levels of USP20 were detected using fluorescence quantitative PCR and Western Blot. Subsequently， the overexpression of USP20 was observed to determine its effect on HIF-α expression. Similarly， siRNA-USP20 was used to knock down USP20 in breast cancer MDA-MB-231 cells， followed by detection of gene and protein expression levels using fluorescence quantitative PCR and Western Blot. The subsequent changes in HIF-α expression were then examined. Rusults The positive expression rates of USP20 and HIF-α in breast cancer tissues were 69.6% and 46.83%， respectively， while they were negatively expressed in the adjacent normal tissues， with statistically significant differences （P < 0.01）. The positive expressions of USP20 and HIF-α were predominantly observed in the cytoplasm of breast cancer tissue， with a smaller amount present in the nucleus. There was a significant positive correlation between USP20 and HIF-α in breast cancer. Following transfection of shRNA-USP20 lentivirus into MDA-MB-231 cells， both the protein and gene expression levels of USP20 significantly increased （P < 0.01）. Over-expression of USP20 did not affect HIF-α mRNA levels but led to a significant increase in HIF-α protein expression （P < 0.01）. Conversely， siRNA-USP20 interference resulted in a significant decrease in both the protein and gene expression levels of USP20 （P < 0.01）， without affecting HIF-α mRNA levels； however， it caused a notable reduction in HIF-α protein expression （P < 0.01）. Conclusion The expression of USP20 exhibited a significant positive correlation with HIF-α in breast cancer. Overexpression of USP20 led to a substantial increase in HIF-α protein expression， while knock-down of the USP20 gene resulted in a significant decrease in HIF-α protein levels. Therefore， it can be inferred that USP20 may exert its influence on the development of breast cancer through modulation of HIF-α expression， thereby providing crucial experimental evidence for clinical treatment， prognosis， and further investigations.
Lingyu FANG , Jinghua HU , Junfeng WEN , Shiqi HAN , Yali WANG , Lulan PU , Jingjia LI , Yi YANG , Shishan DENG , Lingmi HOU , Fangfang. ZHOU . Expression and significance of ubiquitin⁃specific proteases 20 and hypoxia inducible factor⁃1α in breast cancer[J]. The Journal of Practical Medicine, 2024 , 40(16) : 2270 -2276 . DOI: 10.3969/j.issn.1006-5725.2024.16.012
| 1 | ARNOLD M， MORGAN E， RUMGAY H， et al. Current and future burden of breast cancer： Global statistics for 2020 and 2040 ［J］. Breast， 2022， 66：15-23. doi:10.1016/j.breast.2022.08.010 |
| 2 | KASHYAP D， PAL D， SHARMA R， et al. Global Increase in Breast Cancer Incidence： Risk Factors and Preventive Measures［J］. Biomed Res Int， 2022， 2022：9605439. doi:10.1155/2022/9605439 |
| 3 | 荣欣欣， 黄红梅， 李静佳， 等. 乳腺癌中泛素蛋白连接酶E3A与泛素特异性蛋白酶25的表达及其临床意义［J］. 实用医学杂志， 2020， 36（1）： 27-32. doi:10.3969/j.issn.1006-5725.2020.01.006 |
| 4 | WILKINSON L， GATHANI T. Understanding breast cancer as a global health concern［J］. Br J Radiol， 2022， 95（1130）： 20211033. doi:10.1259/bjr.20211033 |
| 5 | GIAQUINTO A N， SUNG H， MILLER K D， et al. Breast Cancer Statistics， 2022［J］. CA Cancer J Clin， 2022， 72（6）：524-541. doi:10.3322/caac.21754 |
| 6 | XIA C， DONG X， LI H， et al. Cancer statistics in China and United States， 2022： profiles， trends， and determinants［J］. Chin Med J （Engl）， 2022， 135（5）：584-590. doi:10.1097/cm9.0000000000002108 |
| 7 | CAO W， CHEN H D， YU Y W， et al. Changing profiles of cancer burden worldwide and in China： a secondary analysis of the global cancer statistics 2020［J］. Chin Med J （Engl）， 2021， 134（7）：783-791. doi:10.1097/cm9.0000000000001474 |
| 8 | HAN D， WANG L， JIANG S， et al. The ubiquitin-proteasome system in breast cancer［J］. Trends Mol Med， 2023， 29（8）：599-621. doi:10.1016/j.molmed.2023.05.006 |
| 9 | LI W， SHEN M， JIANG Y Z， et al. Deubiquitinase USP20 promotes breast cancer metastasis by stabilizing SNAI2［J］. Genes Dev， 2020， 34（19-20）：1310-1315. doi:10.1101/gad.339804.120 |
| 10 | YERLIKAYA A， KANBUR E， STANLEY B A， et al. The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer［J］. Anticancer Agents Med Chem， 2021， 21（1）：20-32. doi:10.2174/1871520620666200811114159 |
| 11 | SPANO D， CATARA G. Targeting the Ubiquitin-Proteasome System and Recent Advances in Cancer Therapy［J］. Cells， 2023， 13（1）：29. doi:10.3390/cells13010029 |
| 12 | ALIABADI F， SOHRABI B， MOSTAFAVI E， et al. Ubiquitin-proteasome system and the role of its inhibitors in cancer therapy［J］. Open Biol， 2021， 11（4）：200390. doi:10.1098/rsob.200390 |
| 13 | 方玲玉， 侯令密， 陈艳茹， 等. 乳腺癌组织中USP20与Ezrin表达的相关性及临床意义［J］. 现代肿瘤医学， 2023， 31（15）： 2850-2854. doi:10.3969/j.issn.1672-4992.2023.15.016 |
| 14 | 杨懿. USP20影响乳腺癌细胞生物学行为及其机制［D］. 南充： 川北医学院， 2019. |
| 15 | LEE S H， GOLINSKA M， GRIFFITHS J R. HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells［J］. Cells， 2021， 10（9）：2371. doi:10.3390/cells10092371 |
| 16 | RASHID M， ZADEH L R， BARADARAN B， et al. Up-down regulation of HIF-1α in cancer progression［J］. Gene， 2021， 798：145796. doi:10.1016/j.gene.2021.145796 |
| 17 | LIU X， XIE P， HAO N， et al. HIF-1-regulated expression of calreticulin promotes breast tumorigenesis and progression through Wnt/β-catenin pathway activation［J］. Proc Natl Acad Sci U S A， 2021， 118（44）：e2109144118. doi:10.1073/pnas.2109144118 |
| 18 | NELSON J K， THIN M Z， EVAN T， et al. USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer［J］. Nat Commun， 2022， 13（1）：2070. doi:10.1038/s41467-022-29684-9 |
| 19 | 曹毛毛， 陈万青. 中国癌症筛查现状［J］. 科技导报， 2023， 41（18）： 11-17. doi:10.3981/j.issn.1000-7857.2023.18.002 |
| 20 | LI Z， WEI H， LI S， et al. The Role of Progesterone Receptors in Breast Cancer［J］. Drug Des Devel Ther， 2022， 16： 305-314. doi:10.2147/dddt.s336643 |
| 21 | GOMPEL A. Hormone and breast cancer［J］. Presse Med， 2019， 48（10）：1085-1091. doi:10.1016/j.lpm.2019.09.021 |
| 22 | KAWIAK A. Molecular Research and Treatment of Breast Cancer［J］. Int J Mol Sci， 2022， 23（17）： 9617. doi:10.3390/ijms23179617 |
| 23 | PARK J， CHO J， SONG E J. Ubiquitin-proteasome system （UPS） as a target for anticancer treatment［J］. Arch Pharm Res， 2020， 43（11）：1144-1161. doi:10.1007/s12272-020-01281-8 |
| 24 | WANG J， XIANG Y， FAN M， et al. The Ubiquitin-Proteasome System in Tumor Metabolism［J］. Cancers （Basel）， 2023， 15（8）： 2385. doi:10.3390/cancers15082385 |
| 25 | SUN T， LIU Z， YANG Q. The role of ubiquitination and deubiquitination in cancer metabolism［J］. Mol Cancer， 2020， 19（1）： 146. doi:10.1186/s12943-020-01262-x |
| 26 | 孙微， 师永红. 去泛素化酶影响低氧诱导因子-1α泛素化过程的研究进展［J］. 临床与病理杂志， 2015，35（11）： 2018-2022. doi:10.3978/j.issn.2095-6959.2015.11.032 |
/
| 〈 |
|
〉 |